Safety of concurrent immune checkpoint inhibitor therapy during postoperative radiotherapy for triple-negative breast cancer: A preliminary retrospective analysis.
Immune checkpoint inhibitors (ICIs) have recently been approved as part of a neoadjuvant therapy plan for triple-negative breast cancer (TNBC). Consequently, the concurrent use of radiotherapy (RT) and ICIs is becoming increasingly common in clinical practice. Combining RT with ICIs may increase the risk of radiation p...